Quick Facts: Uses of Urso

• Supports the management of a specific liver condition known as primary biliary cholangitis (PBC).
• Aids in the dissolution of certain gallstones in individuals who are not candidates for surgery.
• May be considered to help prevent the formation of gallstones in certain patient populations experiencing rapid weight loss.

---

Urso (ursodiol) is a prescription agent used to address specific conditions related to the liver and gallbladder. The medication is primarily intended to support the management of primary biliary cholangitis (PBC), a chronic liver condition. In patients with PBC, Urso may help to support liver function and can be part of a comprehensive strategy to assist in the patient's long-term well-being.

In the context of the gallbladder, this agent may be used to assist in the dissolution of cholesterol gallstones for individuals who may require a non-surgical alternative. It is also indicated to help prevent the formation of new gallstones in individuals undergoing rapid, significant weight loss. Urso functions to reduce the cholesterol content in bile, which may support the prevention of stone formation and facilitate the breaking down of existing ones.

Regulatory References

1. NIH MedlinePlus guidance

Who Can and Cannot Use Urso? Official Regulatory Information

The eligibility for using Urso (ursodiol) is strictly defined by regulatory authorities based on patient population, underlying disease state, and specific physiological conditions. This section details the official eligibility and non-eligibility information as documented in governmental sources.

---

Eligibility Status

Category	Regulatory Status
Established Use	Adults with Primary Biliary Cholangitis (PBC), and those with radiolucent, non-calcified cholesterol gallstones.
Use Not Recommended	Patients with advanced decompensation of hepatic cirrhosis; Women of childbearing potential not using reliable contraception (EU/UK labels).
Contraindicated	Patients with hypersensitivity to ursodiol; Complete mechanical obstruction of the biliary tract; Acute cholecystitis; The presence of calcified or bile pigment gallstones.

---

Population-Specific Limitations

For Age-Related Eligibility, use is generally established in adults for the main indications. Safety and effectiveness have not been established for the general pediatric population (US label). Geriatric age alone does not limit use, but caution is advised in dose selection.

The Pregnancy and Lactation status is highly restricted. Use is either contraindicated or permitted only if clearly necessary, and pregnancy should be excluded before starting treatment (as per official prescribing information). Eligibility is further restricted by disease severity, with use in patients experiencing complications like ascites or variceal bleeding subject to caution or discontinuation.

Interactions with other medicines and products

Ursodeoxycholic acid's official interaction profile is characterized by effects that alter its own absorption, interfere with its action, and modify the plasma exposure of certain co-administered drugs. No medicinal product is formally listed as a contraindicated combination in the regulatory labels.

Administration Timing and Absorption Interference

The regulatory label specifies that bile acid sequestering agents, such as cholestyramine and colestipol, and aluminum-based antacids can reduce the absorption of ursodeoxycholic acid. This interference with absorption mandates that these products must be administered at least two hours before or after Urso.

Pharmacodynamic Counter-Effect

Certain medications, including estrogens, hormonal oral contraceptives, and lipid-lowering drugs like clofibrate, are documented to counteract the effectiveness of ursodeoxycholic acid, particularly when used for gallstone dissolution. This is based on their effect of increasing hepatic cholesterol secretion.

Altered Co-Administered Drug Exposure

Ursodeoxycholic acid has been shown to increase the intestinal absorption of Ciclosporin, which officially requires the monitoring of blood concentrations and dose adjustment. Conversely, co-administration reduces the plasma peak concentrations and area under the curve (AUC) of the calcium antagonist Nitrendipine. A reduction in the therapeutic effect of Dapsone was also reported. Controlled clinical trials have demonstrated that Urso does not have a relevant inductive effect on cytochrome P450 3A enzymes.

Ursodeoxycholic acid (UDCA) operates via a multi-step mechanism centered on modulating the chemical and cellular environment of the biliary system. It functions as a hydrophilic bile acid that achieves its full effect when it constitutes a high proportion of the enterohepatic bile acid circulation.

UDCA exerts a physical-chemical action by indirectly reducing the hepatic secretion of cholesterol and decreasing its intestinal absorption, thereby lowering the cholesterol saturation index of bile. It subsequently promotes the formation of specialized, less-saturated mixed micelles, which increases the capacity of bile to incorporate cholesterol. This physiological adjustment creates a thermodynamically favorable environment where cholesterol partitioning into the micellar phase is favored.

Simultaneously, UDCA provides cellular membrane stabilization. It physically displaces toxic hydrophobic bile acids from the membranes of hepatocytes and cholangiocytes. This incorporation into the cell structure results in the suppression of apoptosis pathways in these cells. Since the mechanism is dependent on UDCA's concentration within the bile acid pool, its full physiological consequences are inherently slow and gradual, and constrained to non-calcified cholesterol deposits.

Ursodeoxycholic acid (Urso/Ursodiol) is a medicine administered solely by the oral route in the form of capsules, tablets, or an oral suspension. The use of this medicine is fundamentally structured around the patient’s body weight and the specific approved indication.

Dosing and Frequency Principles

Typical dosing considerations for Primary Biliary Cholangitis (PBC) range from 13 mg/kg/day to 15 mg/kg/day. For the dissolution of cholesterol gallstones, the dose is often around 8 mg/kg/day to 10 mg/kg/day. The total daily amount is commonly divided into two to four doses taken throughout the day, although some maintenance regimens may transition to a single daily dose.

Administration Conditions

A critical administration instruction is timing; doses are often taken with food to optimize absorption. Furthermore, the largest single dose or the full daily dose (if single-dosing) is typically scheduled to be taken in the evening or at bedtime. Tablets and capsules are intended to be swallowed whole with water. For specific pediatric populations, separate weight-based dosing regimens are utilized.

Duration and Missed Doses

Treatment is characterized by a prolonged course duration. For PBC, the use is often continued indefinitely. For gallstone dissolution, therapy generally requires an extended period, often spanning 6 to 24 months. If a dose is missed, patients should take it when remembered, but must not take a double dose to compensate for the omission.

Research Evidence / Overview of Studies for Urso

Evidence for Use in Primary Biliary Cholangitis (PBC)

The research exploring Urso for Primary Biliary Cholangitis is supported by randomized controlled trials (RCTs) and long-term observational cohort studies. Researchers monitored outcomes related to physiological strain, specifically changes in liver biochemistry, such as Alkaline Phosphatase (ALP) and bilirubin levels. Studies also monitored outcomes related to major long-term endpoints, including liver transplant-free survival.

Studies report how symptoms evolved in the observed adult populations. Multiple trials described patterns where lower ALP and bilirubin levels were measured in the observed populations during the study period. Large registry data also show patterns related to survival when observed over longer periods in real-world settings. However, the evidence also describes that a portion of the studied population did not achieve a full, standardized biochemical response measured in the trials.

Evidence for Cholesterol Gallstone Management

The research explored the use of Urso in the context of cholesterol gallstone dissolution in non-surgical adult populations. Studies explored outcomes related to physical discomfort, with the primary outcome measured was complete gallstone clearance, typically confirmed using imaging tests. This research was primarily conducted using randomized controlled trials to compare outcomes against a control or placebo.

Research describes measured rates of complete gallstone clearance observed in some studies. Findings indicate that the observed outcomes appear to be associated with the initial size and specific composition of the gallstones that were studied. Studies also report patterns showing that gallstones can sometimes re-form in individuals after the observation period ends.

Research on Gallstone Prevention During Rapid Weight Loss

Urso was evaluated in studies specifically exploring the prevention of new gallstone formation in patients undergoing rapid weight reduction, such as after bariatric surgery. RCTs observed a lower rate of new gallstone formation in some studies compared to control groups during the initial post-weight loss period. Evidence is limited regarding the optimal duration of use, and follow-up durations were modest in many of these preventive studies.

What is Still Uncertain About Urso Research

The full characterization of long-term survival endpoints is not fully established, as many initial clinical trials had follow-up durations of only one or two years. Data for certain specific groups, such as those with advanced liver disease or children, remain insufficient. For certain applications, comparative evidence is lacking, making it difficult to fully contextualize the data.

Common questions about Urso (FAQ)

---

Q: Can Urso dissolve calcified gallstones?

Official regulatory documents indicate that Urso (ursodeoxycholic acid) is generally used only for non-calcified cholesterol gallstones. The presence of calcified or radiopaque stones is typically noted as a contraindication in product information. This means Urso is not intended for use with hardened or calcified deposits.

---

Q: How long does it take for Urso to start dissolving gallstones?

Studies and official product information indicate that Urso works slowly and gradually to alter bile composition. Monitoring for initial gallstone dissolution using imaging tests is typically done at 6-month intervals following the start of treatment. The therapy generally requires an extended period, often spanning 6 to 24 months, to achieve dissolution, based on clinical studies.

---

Q: How often will I need to take Urso for Primary Biliary Cholangitis (PBC)?

For the indication of Primary Biliary Cholangitis (PBC), official product information notes that the total daily amount of medicine is commonly divided into two to four doses. Dosing is often administered with food and is determined by a healthcare provider based on the patient's body weight.

---

Q: What happens if I miss a dose of Urso?

Official product information suggests that a missed dose may be taken when it is remembered. However, patients are cautioned to not take a double dose to compensate for a missed dose. If a patient is close to the time for the next scheduled dose, they should follow the regular schedule.

---

Q: How should I store my Urso medication at home?

According to official product labeling, Urso should be stored in its closed container at a cool, dry place known as Controlled Room Temperature (20°C to 25°C). The product labeling specifies that the medication should be kept from freezing, excessive heat, and moisture. It should also be stored out of the reach of children.

---

Q: Does Urso affect blood pressure medication?

The official interaction profile is characterized by effects that alter Urso’s own absorption and modify the plasma exposure of certain co-administered drugs. Specifically, regulatory information reports a reduction in the effect of the calcium antagonist Nitrendipine, which is a type of blood pressure medication. Interactions with other classes of blood pressure medications are not detailed in core labels.

---

Q: What are the signs of an allergic reaction to Urso?

Official product information states that Urso is contraindicated if a patient has a known hypersensitivity to the drug. While serious allergic reactions (such as angioedema) are noted in regulatory reports, the labels commonly list general skin reactions like rash and urticaria (hives) as reported effects.

---

Q: What is the maximum daily dose of Urso that a person can take?

Core regulatory information typically provides dosing based on patient weight and the specific condition being treated, rather than a single fixed maximum amount. However, in studies for gallstone prevention during rapid weight loss, an investigational dose of 600 mg total daily dose (often divided) was utilized.

Storage and Disposal Requirements

Urso (ursodiol) must be stored at Controlled Room Temperature, which is officially defined as 20 C to 25 C (68 F to 77 F). The regulatory labeling permits temporary excursions between 15 C and 30 C. To maintain product stability, the medicine must be stored in a tightly closed container in a dry place and must be kept from freezing.

Child Safety and Handling: The product must be stored out of the reach of children. If tablets are scored for dosing, the broken segments should be stored separately from whole tablets.

Disposal: Disposal of any unused or expired product must be carried out in strict accordance with local and national regulations. Regulatory labeling specifically prohibits flushing Urso into surface water or sanitary sewer systems, as the product must not be released into the environment.